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Natalizumab (NTZ) and autologous hematopoietic stem cell transplantation (AHSCT)
are two successful treatments for relapsing-remitting multiple sclerosis (RRMS),
an autoimmune T-cell-driven disorder affecting the central nervous system that is
characterized by relapses interspersed with periods of complete or partial recovery.
Both RRMS treatments have been documented to impact T-cell subpopulations and
the T-cell receptor (TCR) repertoire in terms of clone frequency, but, so far, the link
between T-cell naive and memory populations, autoimmunity, and treatment outcome
has not yet been established hindering insight into the post-treatment TCR landscape
of MS patients. To address this important knowledge gap, we tracked peripheral T-cell
subpopulations (naïve and memory CD4+ and CD8+) across 15 RRMS patients before
and after two years of continuous treatment (NTZ) and a single treatment course
(AHSCT) by high-throughput TCRß sequencing. We found that the two MS treatments
left treatment-specific multidimensional traces in patient TCRß repertoire dynamics with
respect to clonal expansion, clonal diversity and repertoire architecture. Comparing
MS TCR sequences with published datasets suggested that the majority of public
TCRs belonged to virus-associated sequences. In summary, applying multi-dimensional
computational immunology to a TCRß dataset of treated MS patients, we show that
qualitative changes of TCRß repertoires encode treatment-specific information that may
be relevant for future clinical trials monitoring and personalized MS follow-up, diagnosis
and treatment regimes. Natalizumab (NTZ) and autologous hematopoietic stem cell
transplantation (AHSCT) are two successful treatments for relapsing–remitting multiple
sclerosis (RRMS), an autoimmune T-cell–driven disorder affecting the central nervous
system that is characterized by relapses interspersed with periods of complete or partial
recovery. Both RRMS treatments have been documented to impact T-cell subpopulations
and the T-cell receptor (TCR) repertoire in terms of clone frequency, but, so far, the link
between T-cell naive and memory populations, autoimmunity, and treatment outcome
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has not yet been established hindering insight into the posttreatment TCR landscape
of MS patients. To address this important knowledge gap, we tracked peripheral
T-cell subpopulations (naive and memory CD4+ and CD8+) across 15 RRMS patients
before and after 2 years of continuous treatment (NTZ) and a single treatment course
(AHSCT) by high-throughput TCRβ sequencing. We found that the two MS treatments
left treatment-specific multidimensional traces in patient TCRβ repertoire dynamics with
respect to clonal expansion, clonal diversity, and repertoire architecture. Comparing
MS TCR sequences with published datasets suggested that the majority of public
TCRs belonged to virus-associated sequences. In summary, applying multidimensional
computational immunology to a TCRβ dataset of treated MS patients, we show that
qualitative changes of TCRβ repertoires encode treatment-specific information that may
be relevant for future clinical trials monitoring and personalized MS follow-up, diagnosis,
and treatment regimens.
Keywords: system immunology, T-cell subpopulations, T-cell repertoire diversity, multiple sclerosis, disease-
modifying therapies
INTRODUCTION
Multiple sclerosis (MS) is a heterogeneous, organ-specific,
inflammatory disease where peripheral, myelin-autoreactive T
cells migrate into the central nervous system (CNS) leading to
demyelination. It is currently the most widespread autoimmune
neurological disease, affecting ∼2.5 million people worldwide
(1). Approximately 85% of patients are first diagnosed with
relapsing–remitting MS (RRMS), and the majority of them are
young women (2). Relapsing–remitting MS is characterized by
relapses or exacerbations followed by a period of complete or
partial remission lasting from a few days to several months.
Over the last 25 years, the immunotherapy of MS and other
autoimmune disorders has made considerable progress. Besides
first-line treatments that mainly act as immunosuppressants,
some of the developed medications are able to rebuild
the immune system, inducing profound changes in the
lymphocyte repertoire accompanied by long-term therapeutic
effects (3).
Two successful RRMS disease-modifying therapies are
natalizumab (NTZ), a humanized monoclonal antibody directed
against the integrin α4β1 (or Very Late Antigen-4, VLA-4) that
prevents the migration of pathogenic T cells into the CNS (4),
and AHSCT that resets the immune system and restores immune
tolerance by depleting pathogenic adaptive immune cells (5).
Both treatments are particularly effective in those patients who
have failed previous conventional therapies (6, 7).
Recent reports addressed the potential of these two treatments
to impact on T-cell population balance and T-cell receptor
(TCR) repertoire. The TCR recognizes peptide antigens in the
context of human leukocyte antigen (HLA) molecules and
plays a central role in all immune-mediated disorders. High-
throughput sequencing has paved the way for investigating
TCR repertoire dynamics in peripheral blood mononuclear cells
(PBMCs) and tissue-infiltrating lymphocytes. Previously, several
studies explored the TCR repertoire in autoimmunity such as
diabetes (8, 9) and celiac disease (10), managing to identify an
abnormal TCR repertoire shared among patients.
In MS patients, the TCR repertoire was investigated in blood,
cerebrospinal fluid, and lesions (11, 12). They found that CD4+
and CD8+ cells are expanded in CNS perivascular spaces and in
MS lesions, respectively (13), and that Epstein–Barr virus (EBV)–
reactive clones are compartmentalized and expanded in MS
brain (14). Recently, Jelcic et al. (4) identified TCRβ sequences
shared between an autoproliferative, self-reactive, peripheral
CD4+ T cell population and brain-infiltrating cells in one MS
patient. Furthermore, de Paula Alves Sousa et al. (15) investigated
the peripheral TCR repertoire in MS compared to a viral,
neuroinflammatory disease (human T-lymphotropic virus type
1–associated myelopathy/tropical spastic paraparesis), finding a
group of TCRβ sequences shared exclusively among MS patients.
Natalizumab, through its mechanism of action, was found to
increase the percentage of all immune cell populations in the
peripheral blood (PB), especially central memory (CM) T cells,
themajor fraction ofmemory CD4+T cells, and effectormemory
(EM) T cells (16, 17). In parallel, NTZ increased TCR expansion
in PB (18). AHSCT, in turn, was found to result in a complete
renewal of CD4+ T cells along with the persistence of selected
CD8+ clones (11, 12).
Despite the preliminary progress achieved in understanding
how immunomodulatory treatments rebalance the immune
system in autoimmune disorders and the involvement of the
TCR repertoire, it has remained unknown so far to what
extent RRMS treatments impact the TCR repertoire. Insight
into treatment-induced TCR repertoire changes is of decisive
importance for understanding the effect of RRMS treatments on
the molecular level. To quantify the impact of NTZ and AHSCT
on patient TCR repertoire, we performed TCRβ sequencing of
T-cell subpopulations (naive and memory CD4+ and CD8+)
isolated from PB of 15 RRMS patients before and after 24
months of NTZ or AHSCT treatment for a total of 160
sequenced repertoires. We were able to detect treatment-specific
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TABLE 1 | Clinical characteristics of natalizumab patients.
No. of patients 8
Gender (female:male) 8:0
Age average (min–max) 39.5 (28–45)
Age at treatment initiation average (min–max) 38.5 (21–39)
Type of MS RRMS
Disease duration average (min–max) 14.3 (8–21)
EDSS T0–T24 average (min–max T0; min–max
T24)
3–2.1 (1.5–4.5; 1–3.5)
No. of patients with relapses before
natalizumab (AIFA criteria A:B)#a
8/8 (5:3)
No. of patients positive for anti-JCV Absa 7/8
No. of patients with relapsesb 3/8
No. of patients with disease activity (MRI)#b 2/8
No. of patients developing anti-natalizumab
Absb
1/8
No. of patients with washout relapses 4/8
Therapyc
IFN-β
6/8
Copaxone 1/8
Azathioprine 3/8
No therapies 1/8
#apatients who failed the first line therapy, with high disease activity: two relapses in the
last year of therapy or one relapse with not complete recovery and up to 9 lesions T2 in
MRI or one Gd+ lesions.
#bRapidly evolving patients, with 2 or more relapses in 1 year and 1 or more Gd+ lesions/a
significative increment of T2.
aAt the first natalizumab administration.
bDuring natalizumab therapy.
cWashout period between natalizumab and previous first-line treatments of at least
1 month.
molecular and phenotypical traces in RRMS patients, particularly
in TCR clonal expansion distribution, clonal persistence across
timepoints, TCR repertoire architecture, and serum cytokine
(CK) levels.
METHODS
Patients
All patients included in the study were enrolled at the Clinic of
the Second Division of Neurology, Careggi University Hospital,
Florence, Italy. Diagnosis of RRMS was performed according
to Carroll and McDonald criteria (19). During treatments
(AHSCT; NTZ), RRMS patients were followed monthly and
evaluated collecting clinical, magnetic resonance imaging (MRI),
and laboratory data. Patient characteristics are summarized
in Tables 1, 2.
AHSCT Patients
Patients were included in AHSCT according to the following
characteristics: patient age ranged between 18 and 60 years;
Expanded Disability Status Scale (EDSS) between 1 and 6.5;
RRMS diagnosis, with MRI activity and/or clinical worsening
of the disability despite treatment in the 6 months before
the enrollment; and refractory to treatment with NTZ or
impossibility to perform this therapy due to allergic reaction
TABLE 2 | Clinical characteristics of AHSCT patients.
No. of patients 7
Gender (female:male) 7:0
Age average (min–max) 39.9 (31–47)
Age at treatment initiation average (min–max) 32.7 (21–47)
Type of MS RRMS
Disease duration average (min–max) 19.7 (13–38)
EDSS before AHSCT average (min–max) 4.9 (2.5–6.5)
EDSS after AHSCT average (min–max) 4.4 (1.5–6.5)
No. of patients with relapses before AHSCTa 6/7
No. of patients with disease progression before
AHSCTa
0/7
No. of patients with relapses after AHSCTb 1/7
No. of patients with disease progression after
AHSCTb
0/7
Therapy
Natalizumabc
4/7
Cyclophosphamide 3/7
Copaxone 2/7
Azathioprine 2/7
IFN-β 4/7
Mitoxantrone 2/7
No therapies 0/7
aDuring the 2 years before the transplant.
bDuring the 2 years after the transplant.
cWashout period between natalizumab and AHSCT of at least 6 months.
to the drugs or presence of neutralizing antibodies. For
AHSCT patients who were previously treated with NTZ,
the washout period between NTZ and AHSCT was of at
least 6 months.
AHSCT Protocol
Peripheral blood stem cells (PBSCs) from patients were
mobilized by cyclophosphamide (4 g/m2) and filgrastim (5µg/kg
from). Cells were collected by continuous flow leukapheresis
(two whole body blood volumes) when circulating CD34+ cells
exceed 20/µL of whole blood; 3–8 × 106 CD34+ cells/kg were
collected and stored in liquid nitrogen. Conditioning regimen
included carmustine (300 mg/m2 per day), cytosine arabinoside
(200 mg/m2 per day), etoposide (200 mg/m2 per day), and
melphalan (BEAM) (140 mg/m2 per day) for 3 consecutive
days. Rabbit anti-T globulin (ATG; ThymoglobulineTM) was
administered at day +1 and +2 at a total dosage of 7.5
mg/kg. During the reduced intensity conditioning phase,
cyclophosphamide (50 mg/kg per day) and ATG (2.5 mg/kg)
were administered at +2 and +6 and at +2 and +4,
respectively. Biological samples from RRMS patients before
(t0) and 24 months (t24) after AHSCT were collected at
the Hematology Unit, Careggi University Hospital. Antibiotic
and antiviral prophylaxis was administered during the phase
of aplasia according to hematology unit practice. At t0,
immunosuppressive treatments were stopped at least 1 month
before sample collection.
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NTZ Patients
All RRMS patients included in the study failed the first-line
treatments and had high disease activity, which means two
relapses in the last year of therapy or one relapse with no
complete recovery and up to nine lesions T2 in MRI or
one gadolinium positive (Gd+), or showed rapidly evolving
patients, which means two or more relapses in 1 year and
one or more Gd+ lesions or with a significative increment
of T2 lesions. Patients included in this study shared the
following characteristics: age between 18 and 60 years; EDSS
score between 0 and 5.5. Inclusion and exclusion criteria
are described in detail in SURPASS study (ClinicalTrials.gov
identifier NCT01058005). Presence of anti-JCV and anti-NTZ
antibodies in serum was evaluated. Peripheral blood (40mL)
for each MS patient under NTZ treatment was collected at
baseline (t0, at least 1 month free of treatment) and after 24
months (t24) of treatment at the Clinic of the Second Division
of Neurology, Careggi University Hospital. Natalizumab patients’
washout period from previous treatments was of at least 1 month
from first-line immunomodulatory treatments [e.g., glatiramer
acetate (Copaxone) and interferons].
Study Approval
This study was performed according to the Declaration of
Helsinki. For all AHSCT and NTZ patients, signed informed
consent was collected and approved by the Local Ethical
Committee (#467/11; #CEAVC12745).
Clinical Follow-Up of RRMS-Treated
Patients
To date, 13 of 15 patients are still followed at the Second Division
of Neurology, Careggi University Hospital.
Among the patients who underwent AHSCT, only one
(MS032) experienced a relapse at 2 years from AHSCT; of note,
MS032 has a family history of MS and interrupted the standard
protocol of conditioning chemotherapy to minimize infection
risk, subsequently to positivity to the multidrug-resistant strain
of Klebsiella pneumoniae. MS020, MS029, MS032, and MS034
were treated with NTZ before transplantation, and MS029 is the
only one that interrupted NTZ treatment after the development
of antibodies against John Cunningham virus (JCV).
Among the NTZ patients, Ty20, Ty21, and Ty25 experienced
disease relapses during treatment, whereas MRI brain
inflammatory activity (defined as new MRI T2 lesions or
Gd-enhancing lesions) was present in patient Ty29. Ty12, Ty17,
Ty21, Ty25, and Ty26 suspended the treatment because of JCV
positivity. None of the NTZ-treated patients showed a positive
signal for anti-NTZ antibodies. Anti-JCV antibodies were
present in all patients except for Ty20. During NTZ, Ty26 had an
ischemic stroke, and Ty30 developed depression and was lost at
the follow-up; no other concomitant disease has been reported.
During washout after NTZ, Ty12, Ty20, Ty25, and Ty26 had
relapses. Ty21 suspended NTZ for JCV+ and the ineffectiveness
of treatment.
Of note, patients from both groups are comparable in terms of
demographic (age, sex) and clinical (diagnosis, disease duration)
characteristics, and all of them underwent similar treatments
before NTZ or AHSCT, with no prevalence of a specific
pretreatment among others.
PBMCs and Serum Collection
Peripheral blood mononuclear cells: whole PB has been collected
in heparin-containing tubes; mononuclear cells (MNCs) were
collected by density gradient centrifugation using Pancoll
(density: 1.077 g/mL; PAN-Biotech, Germany) at 1,500 rpm,
room temperature (RT), for 30min within 6 h from blood
collection. Mononuclear cells were cryopreserved in 10%
dimethyl sulfoxide in aliquots containing 20 × 106 cells and
stored in liquid nitrogen freezer until used.
Serum
Serum samples were collected according to the same time
schedule and in the same vein puncture as performed for PB
collection. For each time point, 10mL of blood was drawn in
serum-separated tubes. Serum was separated from clotted blood
by centrifugation at 3,000 rpm for 10min, RT and then aliquoted
and stored in−80◦C freezer until used.
CD3+ Cells Isolation
CD3+ cells were isolated from at least 25 × 106 PBMCs.
Peripheral blood mononuclear cells were thawed in defrosting
medium (10% fetal calf serum in Dulbecco’s phosphate-buffered
saline), centrifuged at 1,300 rpm, RT, for 10min, then counted
and used for T-cell isolation by negative immunomagnetic
depletion using the Pan T Cell Isolation Kit human (Miltenyi
Biotec, Germany), consisting in a Pan Cell Biotin-Antibody
Cocktail and a Pan T Cell MicroBead Cocktail that provide the
retention of the unwanted cell fraction (CD3-negative cells) and
the elution of the CD3+ cells fraction through the LS column
placed on a suitable MACS Separator (Miltenyi Biotec). Mean
CD3+ cells value per sample was 4× 106 (±2.2).
Flow Cytometric Isolation of T-Cell
Subpopulations
AHSCT Patients
CD3+ cells were washed once inMACS buffer (PBS 1Xwith 0.5%
bovine serum albumin and 2mM ethylenediaminetetraacetic
acid) at 1,500 rpm, RT, for 5 minutes, and then resuspended
in RPMI 1640 medium and counted. To identify naive and
memory CD4+ and CD8+ T lymphocytes, CD3+ cells were
labeled in one tube for 20min, RT, in the dark, with the following
fluorescent antibodies: anti-CD4 APC (clone: OKT4), anti-CD8
PE Cy7 (clone: RPA-T8), and anti-CD45RA FITC (clone: HI100),
all from eBioscience, USA. T-cell subpopulations were sorted by
FACSAria II flow cytometer (BD Bioscience).
NTZ Patients
Purified CD3+ cells were washed and counted as described
above. To identify naive, EM, CM CD4+ and CD8+, and
TEMRA CD8+ T lymphocytes, cells were divided in two tubes
and labeled for 20min, RT, in the dark, with the following
fluorescent antibodies: one tube with anti-CD4 APC (clone:
OKT4), anti-CD45RA FITC (clone: HI100), and anti-CCR7 PE
(clone: 3D12); and the other one with anti-CD8 PE Cy7 (clone:
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RPA-T8), anti-CD45RA FITC (clone: HI100), and anti-CCR7
PE (clone: 3D12). All the antibodies are from eBioscience. T-
cell subpopulations were sorted by FACSAria II flow cytometer
(BD Bioscience).
HLA II Genotyping
All patients were typed for HLA class II by sequence-specific
primer PCR (PCR-SSP) technique using the AllSet+TM Gold SSP
Low-Resolution kit (One Lambda).
Cytokine and Chemokine Evaluation
Serum samples were analyzed for the determination of a panel
of 17 CKs and chemokines [interferon γ (IFN-γ), interleukin 4
(IL4), IL1α, IL1β, IL2, IL6, IL8, IL10, IL12p40, IL12p70, IL17,
IL23, tumor necrosis factor (TNFα), GM-CSF, CXCL10, CXCL13,
MMP9] by Bioplex device (Biorad) using Milliplex assay (Merck
Millipore), following the manufacturer’s protocol.
RNA Isolation
RNA was isolated immediately after sorting by using the
RNeasy Plus Micro Kit (Qiagen, Netherlands), according to the
manufacturer’s protocol. RNA purity was assessed by NanoDrop
ND-1000 spectrophotometer (EuroClone, Italy) evaluating the
260/280 nm absorbance. RNA concentration (pg/µL), rRNA
ratio [28S/18S], and RNA Integrity Number (RIN) were assessed
using the RNA 6000 Pico Kit (Agilent, USA), according to
the manufacturer’s recommendations, and analyzed by Agilent
BioAnalyzer 2100.
TCR Library Generation and RNA
Sequencing
The generation of TCR libraries and next-generation sequencing
(NGS) of RNA from sorted T cell subsets was performed by the
amplification and sequencing services offered by iRepertoire Inc.,
Huntsville, AL, USA, a company highly specialized in NGS of
TCR repertoires. Briefly, TCR Vβ chain libraries were prepared
by the patented tem-PCR (for target enriched multiplex PCR
technology), developed by iRepertoire Inc., based on the use
of nested primers designed to be coamplified in the multiplex
assay, and “superprimers,” which act together with the nested
primers in two PCR rounds. After purification, amplified TCRβ
chain libraries were sequenced byMiSeq Illumina platform, using
250 PER (paired-end read) primers, which cover framework 1
to C-region.
Statistics
Repertoire Data Analysis
Statistical analysis of TCRβ sequence data was performed using
the statistical programming environment R (20). Graphs were
generated using the R packages ggplot2 (21), ggpubr (22),
igraph (23), and ComplexHeatmap (24). Hierarchical clustering
of evenness profiles was performed based on correlation-based
distance and visualized by heatmaps using the NMF R package
(25). Repertoire architecture networks were visualized using
Cytoscape (26).
Shannon Evenness and Clonal Expansion Profiles
Shannon–Evenness (S-E) and clonal expansion profiles were
calculated as previously established by us (27). Briefly, the S-E is
defined as the quotient of the exponential of the Shannon entropy
and species richness (SR: number of unique CDR3s in a given
TCR dataset).
Shannon-Entropy = −6 fi log fi,
where fi is the frequency of the ith clone in a given TCR dataset.
S-E = exp(−6 fi log fi)/SR
Shannon–Evenness is 1 if all clones in a repertoire have the same
frequency (an “even” repertoire), or it converges to 0 if very few
clones dominate in the repertoire (a “polarized” repertoire), that
is, if very few clones have very high frequency and a lot of clones
have a very low frequency.
Clonal expansion profiles (also called Evenness profiles)
represent Hill diversity profiles scaled by the repertoire SR. Hill
diversity profiles are defined as:
qD =
(
SR∑
i=1
f
q
i
) 1
1− q
,
where f i is the frequency of the ith clone in a given TCR dataset.
Clonal expansion profiles are then defined as qD/SR, where q
ranges from 0 to 10 with a step size of 0.2. The parameter
q determines the importance of high-frequency clones in the
determination of the q-parameterized evenness; the higher q, the
more high-frequency clones are weighted (28).
k-mer–Based CDR3 Subsequence Analysis
All CDR3s–amino acid (a.a.) from each patient’s TCR repertoire
were deconstructed into overlapping subsequences (“k-mers”)
of length 3 (k = 3) using the tokenizers R package (29). Then,
all k-mers were condensed into a k-mer frequency distribution
containing each k-mer’s frequency across all CDR3s of a given
repertoire. Finally, k-mer frequency distributions were correlated
across repertoires using Pearson correlation and visualized using
hierarchical clustering and heatmap as described above.
Definition and Quantification of Clonal
Persistence (Overlap)
A clone is defined as V-J-CDRβ3 (a.a. sequence). Pairwise clonal
persistence between repertoires A and Bwas calculated as follows:
Clonal persistence (A, B) =
A ∩ B
mean(|A| , |B|)
,
where A n B is the absolute number of persisting clones, and |A|
signifies the number of clones in repertoire A. Clonal persistence
was calculated across treatments (t0–t24) for each patient.
Private and Public Clones
A clone (V-J-CDRβ3 a.a.) was considered private when present
in only one repertoire and public when shared at least across
two repertoires.
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Network Analysis
Networks of TCRβ repertoires were constructed as previously
described (30, 31). Briefly, for each repertoire, a network was
drawn using the R package igraph (23) based on the top 10,000
(or less if fewer clones were found in a patient’s repertoire)
a.a. CDR3 sequences (top 10,000 represented for all repertoires
more than 90% of sequencing reads). Within each network, each
node is a CDR3, and links between nodes were drawn if the
internode Levenshtein distance (LD) is maximally 1 (=1 a.a.
sequence change). Degree distributions of each repertoire were
also determined using the igraph degree -function. The degree of
a node is the number of nodes it has links to (=number of CDR3s
1 a.a. change apart).
Description of Publicly Available Datasets
Used
Our TCRβ data were compared with three other datasets briefly
described in the following. TheMcPAS-TCR database ismanually
curated and stores TCR sequences associated with various
pathologies and antigens based on published literature (32). The
McPAS-TCR data here analyzed were downloaded on September
29, 2018. VDJ-DB is a database that stores and aggregates the
results of published T-cell specificity assays coupling antigen
specificities with TCR sequences (33). The VDJ-DB data here
analyzed were downloaded on March 31, 2019.
The Jelcic et al. dataset includes TCR sequences from CD4+
and CD8+ memory cells and brain lesions of 2MS patients
(4). The Jelcic et al. dataset here analyzed was downloaded on
November 16, 2018.
Data Availability of TCRβ Dataset
The TCR sequencing data have been deposited under the
following doi: 10.5281/zenodo.3703310.
RESULTS
TCRβ Repertoire Sequencing Data
Acquisition and Statistics
From 15 RRMS patients (eight NTZ and seven AHSCT; see
section Methods for patient enrollment and characteristics), we
sequenced the TCRβ from T-cell subpopulations [naive, EM, CM
CD4+ and CD8+ and terminally differentiated EM (TEMRA)
CD8+ for NTZ; naive and memory CD4+ and CD8+ for
AHSCT] sorted from PBMCs before (t0) and after 24 months
(t24) of treatment, obtaining a total number of 57,330,057
reads and 1,500,769 total number of V-CDR3-J a.a. clones. The
experimental workflow is displayed in Figure 1A.
First, to confirm that our sequencing depth allowed sufficient
clonal coverage of each repertoire, we determined the correlation
of the number of reads, the number of clones (clone definition:
V-CDR3-J a.a. sequence), and S-E (see section Methods for
a definition of S-E) vs. the number of sorted cells and then
between reads and clones number, reads number and S-E, and
clones and S-E (Figure 1B). We found the Pearson correlation
values to be negative in all cases, thereby signifying sufficient
sequencing depth.
We next evaluated the variation, across treatments, of the
number of cells, reads (the total number of sequencing reads
in for each repertoire), clones (the total number of unique V-
CDR3-J a.a. sequences in each repertoire), and S-E by T-cell
subpopulation at t0 and t24 (Figure 1C). We found that NTZ,
in contrast to AHSCT, induces a significant (p < 0.05) repertoire
polarization (S-E closer to 0: few clones dominate) in CD8 naive
cells from t0 (S-E mean value = 0.3) to t24 (S-E mean value
= 0.12), as well as a significant (p < 0.01) reduction in the
number of clones (t0: ≈8,700, t24: ≈2,000). V gene usage did
not differ between RRMS treatments or across timepoints (data
not shown).
When following common repertoire statistics on an individual
basis, treatment-specific traces are challenging to quantify
and visualize (Figure S1). Indeed, when individual repertoire
dynamics across timepoints are analyzed, patient variability
is high, and no specific trends were apparent. Furthermore,
as previously described and shown (33, 34), conventional
low-dimensional statistical approaches such as performed
in Figure 1 or Figure S1 are not suitable for analyzing
the high-dimensional sequence diversity of immune receptor
repertoires. Therefore, in the following, we move to more
complex measures of immune repertoire comparison. These
measures will be applied on an ensemble basis investigating
all repertoires at once. As opposed to following patients on
a single repertoire basis (Figure S1), ensemble measures allow
capturing global trends and minimize potential technological
and biological noise inherent to immune receptor repertoire
datasets (28, 35, 36) .
T-Cell Receptor Clonal Expansion Is
Differentially Driven by AHSCT and NTZ
First, we asked whether clonal expansion is differentially
driven by RRMS treatment. To this end, we analyzed
clonal expansion using previously established Hill-based
evenness profiles (27). Hill evenness profiles have been
developed in mathematical ecology and allow a fine-
grained comparison of clonal expansion across patient
TCRβ repertoires. This analysis evidences differences in
clonal expansion among the two treatment groups both for
CD4+ and CD8+ T-cell subpopulations (Figures 2A,B and
Figure S2A).
Given the documented genetic association of HLA class II
haplotype DRB1∗1501 with MS susceptibility (37), we next asked
whether clonal expansion differed by HLA-DRB1∗1501 type (–
/+) and found that HLA class II type impacts on CD4+ clonal
expansion (Figure S2A). Although it is known that CD4+ T cells
interact with HLA class II, it was interesting to observe a global
effect of HLA class II on the entire CD4+ T-cell population
encompassing both antigen-specific and non-disease-involved
T cells.
To sum up, clonal expansion seems differentially driven
by each treatment both in CD4+ and CD8+ subpopulations.
Furthermore, CD4+ T cell expansion differed by HLA
II type. No difference in clonal expansion was detected
between timepoints.
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FIGURE 1 | Experimental and computational workflow and T-cell receptor (TCR) repertoire sequencing correlation plots and statistics. (A) Peripheral blood
mononuclear cells (PBMCs) and serum were collected from relapsing–remitting multiple sclerosis (RRMS) patients (n = 15) before (t0) and after 24 months (t24) of
(Continued)
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FIGURE 1 | AHSCT (n = 7) or natalizumab (NTZ; n = 8). Serum samples were analyzed for the presence of CKs and chemokines. CD3+ cells were isolated from
PBMCs and T-cell subpopulations [naive, effector memory (EM), central memory (CM) CD4+ and CD8+, and terminally differentiated EM (TEMRA) CD8+ from NTZ
patients; naive and memory CD4+ and CD8+ from AHSCT patients] were isolated. Subsequently, from total mRNA TCRβ chain (TCRβ) sequencing was performed by
iRepertoire Inc. High-dimensional TCRβ data analyses included repertoire sequencing statistics, repertoire architecture, clonal expansion distribution, sequence
similarity, clonal persistence across time points, and comparison with public TCRβ databases. (B) Plots report the Pearson correlation coefficient (r) between reads
(#Reads) and cell numbers (left, first row), clones (#Clones) and cell numbers (middle, first row), Shannon–Evenness (S-E) and cell numbers (right, first row), and then
between #Clones and #Reads (left, second row), S-E and #Reads (middle, second row), and S-E and #Clones (right, second row) of AHSCT (red points) and NTZ
(blue points) repertoires. The S-E quantifies the extent of clonal expansion in each repertoire where values closer to 0 mean high clonal expansion, and values closer to
1 mean low clonal expansion (see section Methods for details). Each point in the correlation plots represents a single TCR repertoire within the two cohorts. Pearson
correlation values for each group of patients (in red for AHSCT and in blue for NTZ) are reported on the upper left of each plot. (C) Cell number, #Reads, #Clones, and
S-E of T-cell subpopulations in NTZ (blue) and AHSCT (red) patients at t0 (left panel) and t24 (right panel). Mean values are shown above each boxplot for all T-cell
subpopulations, which are placed on the x-axis for both time points, in this order from left to right: CD4 naive, CD4 memory, CD4CM, CD4 EM, CD8 naive, CD8
memory, CD8CM, CD8 EM, CD8 TEMRA. Statistical significance was determined by Wilcoxon test (*p < 0.05; **p < 0.01).
Clonal Persistence Is Differentially
Impacted by RRMS Treatments
We then examined clonal persistence (see section Methods),
from t0 to t24, of TCRβ clones across T-cell subpopulations
and treatments.
We found that, for both treatments, clonal persistence is
generally higher in the CD4+ and CD8+memory compartment
as opposed to the naive T-cell compartment (Figure 3). In NTZ
patients, the percentage of persistent clones across timepoints is
higher in CD4+ (0.1–18.5%) and CD8+ (0.4–35.8%) memory
subpopulations compared to AHSCT patients (0.2–9.6% and
2.2–15.7% in CD4+ and CD8+ memory cells, respectively). Of
note, in both groups of patients, we observed exceptions: patient
MS032, who received a different conditioning chemotherapy
during transplantation compared to the other patients, showed
the highest observed percentage of clonal persistence of all
AHSCT patients (15.7% in CD8+ memory and 9.6% in CD4+
memory), whereas in the NTZ group, Ty17, Ty21, and Ty25 (of
whom Ty21 and Ty25 experienced a relapse during treatment)
differed from the other NTZ patients by showing no or very low
clonal persistence in most cell subpopulations.
AHSCT Patients Share a Higher Number of
T-Cell Clones Compared to NTZ
Next, we investigated the percentage of public clones shared
across all patients of both groups, where a clone was defined
as public when shared between at least two patient repertoires
(Figure 4). When investigating those clones that are highly
shared across repertoires, we found a group of clones exclusively
shared among AHSCT patients (Figure 4B). These clones were
largely not clonally related (different V, J usage, very different
CDR3 a.a. sequences) and present in both CD4+ and CD8+ T-
cell subpopulations (Figure S3). Quantitatively, the percentage
of highly shared public clones was found to be significantly
(p < 0.05) higher in CD4+ and in CD8+ (p < 0.01) naive
cells of AHSCT patients compared to NTZ at t0 and at t24,
respectively (Figure 4C).
T-Cell Repertoire Architecture Is Impacted
by RRMS Treatment
The architecture of an immune repertoire represents the all-
to-all sequence similarity of its composing immune receptor
sequences. Thus, repertoire architecture is a direct correlate of
antigen recognition breadth: if all immune receptor sequences
were very similar to one another, then recognition breadth would
be poor, in contrast, if sequences were more dissimilar, a larger
space of the antigenome would be covered. Given the importance
of repertoire architecture for the function of the adaptive immune
response, we asked to what extent patient TCR repertoires differ
from patients having undergone different RRMS treatment.
Repertoire architecture (all-to-all sequence similarity within
a repertoire) may be quantified in several ways: here we
investigated repertoire architecture by both network and
subsequence (k-mer) analysis.
For network analysis of repertoire architecture, we determined
the sequence similarity of all sequences composing a repertoire
by recording for each CDR3s whether it differed in maximally
1 a.a. from all other CDR3s of repertoire (see section Methods)
(30, 31).We focused on changes of 1 a.a. as theymay reflect clones
with similar antigen-binding profile (38, 39). We found that
treatment groups differed in repertoire architecture as evidenced
by differences in degree distributions. The degree of a CDR3 in
a network is the number of its connections (clones differing by
maximally one a.a.). The degree distribution then enumerates the
number of CDR3s with an identical degree. AHSCT repertoires
have many more clones with degree 0 (no similar clones in
the repertoire) compared to NTZ repertoires. This was true
for both CD4+ and CD8+ subpopulations (Figure 5A). In
CD4+ subpopulations, we observed additional clustering by
HLA DRB1∗1501 (Figure S4). Of interest, differences in clonal
connectivity were mostly located in the private part of TCR
repertoires. Public clones showed fewer unconnected clones.
This is in line with previous studies in healthy human controls
(31, 40). Further, the connectivity of public and private clones
percentage tended to increase in NTZ compared to AHSCT at t24
as evidenced by a significant (p < 0.01) increase in CD8+ naive
compartment connectivity from t0 to t24 (Figure 5D).
To complement the network-based repertoire analysis, we
additionally investigated the similarity of CDR3 subsequence
distributions across repertoires (40). In order to investigate
TCR sequence similarity across treatments, timepoints, cell
subpopulations, and haplotype, NTZ- and AHSCT-treated
patients were analyzed based on subsequence length of 3 a.a. (3-
mers). Briefly, all CDR3 sequences of each repertoire were cut
into overlapping 3-mers, which were then aggregated to calculate
the frequency of each 3-mers. 3-Mer frequency was analyzed
across repertoires by correlation. We found that AHSCT patients
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FIGURE 2 | T-cell receptor clonal expansion is differentially driven by treatment. (A) Heatmap of the pairwise Pearson correlation between all (CD4 and CD8)
Shannon–Evenness profiles (or “state of clonal expansion”). This representation of data allows determining to what extent clustering of clonal expansion is driven by
certain parameters such as in our case: treatment, cell subpopulations, timepoint, and HLA class II. Pearson correlation values range from ≈0.5 (blue) to ≈1 (red).
Color bars on the top of the heatmap indicate treatment (AHSCT in red, NTZ in blue), T-cell subpopulation (different shades of pink or green are reported for CD4+ or
CD8+ subpopulations, respectively), timepoint (t0–t24 in light and dark blue, respectively), and HLA class II of patients when DR1501+ (white) or DR1501– (black).
The heatmap x-axis labels indicate T-cell subpopulation, and the y-axis labels indicate sample name. Hierarchical clustering of evenness profiles was performed using
correlation-based distance. (B) Heatmap of the Pearson correlation between CD4 Shannon–Evenness profiles (or “state of clonal expansion”). Color bars on the top of
the heatmap indicate treatment (AHSCT in red, NTZ in blue), CD4+ cell subpopulation (shades of pink), timepoint (t0–t24 in light and dark blue, respectively), and HLA
class II of patients when DR1501+ (white) or DR1501– (black). The heatmap x-axis labels indicate T-cell subpopulation, and the y-axis labels indicate sample name.
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FIGURE 3 | Clonal persistence is differentially impacted by treatment. Percentage of clonal persistence (V-J-CDR3β amino acid overlap) from t0 to t24 is reported for
all T-cell subpopulations of AHSCT (patient IDs: MS002, MS003, MS020, MS029, MS032, MS034, and P) and NTZ (patient IDs: Ty12, Ty17, Ty20, Ty21, Ty25, Ty26,
Ty29, Ty30) patients. Overlap data are reported across subpopulations per patient as an independent table entitled with the respective patient ID. In all tables, the
percentage of clonal persistence is reported for each T-cell subpopulation vs. all other subpopulations tested. See section Methods for details on the numerical
determination of clonal overlap.
showed higher TCR subsequence similarity than NTZ patients
(Figure 6 and Figures S2B,C) indicating higher preservation of
repertoire architecture across AHSCT patients.
To sum up, while NTZ repertoires showed a higher similarity
within repertoires (more connected clones), NTZ repertoires
exhibited poor preservation of TCR repertoire architecture
across repertoires.
The Majority of Shared Sequences
Between RRMS Cohorts and Public
Databases With TCRs of Known Disease
Association Are Viral Infection Associated
Several viruses, for example, EBV (14), have been suggested as
a possible risk factor for MS development. Furthermore, NTZ
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FIGURE 4 | CD8 naive cells of natalizumab patients share less public clones compared to AHSCT at t24, and a group of clones is exclusively shared among AHSCT
patients. (A) Public clones (V-J-CDR3β amino acid) per sample shown by T-cell subpopulation as absolute number (upper panel) or as a percentage (lower panel) in
(Continued)
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FIGURE 4 | AHSCT (in red) and NTZ (in blue) patients at t0 (left panel) or t24 (right panel). T-cell subpopulations are reported on the x-axis for both timepoints in this
order from left to right: CD4 naive, CD4 memory, CD4CM, CD4 EM, CD8 naive, CD8 memory, CD8CM, CD8 EM, CD8 TEMRA. (B) TCR clones shared among more
than 10 samples visualized by treatment (AHSCT in red, NTZ in blue), T-cell subpopulation (CD4+ or CD8+ subpopulations in different shades of pink or green,
respectively), patient ID, timepoint (t0–t24 in light and dark blue, respectively), and by HLA class II of patients when DR1501+ (white) or DR1501– (black). The list of
TCR clones is reported on the left and sample name on the top of the heatmaps (it is necessary to magnify the figure to read the labels). (C) Statistics of public clones
shared among more than 10 samples as shown in (B) in the two groups of patients (AHSCT in red, NTZ in blue) shown by T-cell subpopulation at t0 (upper panel) and
t24 (lower panel). Statistical significance was determined by Wilcoxon test (*p < 0.05; **p < 0.01).
and AHSCT expose patients to the risk of viral reactivation.
Therefore, we asked whether our RRMS dataset included CDR3
sequences already reported in public CDR3 repositories as viral-
infection associated.
To this end, we quantified the CDR3 sequence overlap
between our dataset and three public CDR3 databases, which
store TCR clones of known disease association and/or antigen
specificity: McPAS-TCR (32), VDJdb (32), and the TCRβ
sequencing dataset from the work of Jelcic et al. (4), who
identified a population of proliferative peripheral T cells that
share clones with MS lesions (13).
At the time of download (see section Methods), McPAS-TCR
(Figure S5A) included 1,297 sequences putatively associated
with autoimmune diseases, 6,979 associated with pathogens out
of which most are influenza, cytomegalovirus (CMV), EBV,
and few MS-associated (118). VDJdb (Figure S5B), including
a total of 2,459 human-associated sequences, stored several
viral-associated CDR3s, out of which CMV (5,776), human
immunodeficiency virus 1 (2,637) and EBV (1,825)–associated
CDR3s are the most represented. The Jelcic et al. dataset
(Figure S5C) reported information on patient origin (MS1
and MS2), CD4+/CD8+ memory cells, peripheral or brain-
infiltrating cells, and auto-proliferative or non-auto-proliferative
cells as previously described by authors (4). The highest number
of CDR3s (60,449) was identified among the non-proliferative
PBMCs of patient MS2.
We found that the percentage of overlapping CDR3s between
our repertoires and all the examined databases (McPAS-TCR,
VDJdb and Jelcic et al., Figures 7A–C) is significantly (p < 0.01)
lower in CD8+ naive cells of NTZ patients compared to AHSCT
at t24.
Last, comparing our repertoires with McPAS-TCR
(Figure 8A) or VDJdb (Figure 8B) displayed by disease
type, we found major overlap with viral infection–associated
sequences. We found no substantial overlap between our dataset
and MS-associated CDR3s (Figure 8A).
Serum Cytokines Discriminate Between
the Inflammatory Status of AHSCT and
NTZ
T-cell receptor repertoire variation may be accompanied
by alterations in CK production that may govern
T-cell differentiation.
Among all the CKs and chemokines measured in serum (see
section Methods), we found that TNFα was significantly (p <
0.01) lower in NTZ at t0, whereas at t24, it was significantly
increased (p < 0.05) compared to AHSCT (Figure S6). These
findings indicate an increase in TNFα production in NTZ vs.
a stable production in AHSCT over the timeline of this study.
On the contrary, recall chemokines CXCL10 and CXCL13 are
significantly (p < 0.05) increased at t24 in AHSCT patients
compared to NTZ.
DISCUSSION
Natalizumab and AHSCT are two effective RRMS treatments,
both able to reduce the disease relapse rate in the long term.
Hiere, we asked how NTZ and AHSCT impact the adaptive
TCR-driven immune response. In the future, such information
may facilitate the understanding of the connection between the
treatment mechanism of action and patient clinical outcome. In
general, we demonstrated that it is possible to detect treatment-
specific molecular traces in RRMS patients by high-dimensional
analysis of the core molecule of antigen recognition, TCR, in
different T-cell subpopulations before and after 24 months of
immunotherapy. This is a head-to-head comparison of treatment
impact, and the groups at t0, virtually identical, are the control
baseline values.
Our results show at t24 a significantly less diverse TCR
repertoire of CD8+ naive cells of NTZ patients compared
to AHSCT (Figure 1C). CD8+ naive repertoire diversity is
commonly higher compared to memory (CM, EM, and TEMRA)
CD8+ subpopulations (41), and it represents, along with cross-
reactivity, the major strategy adopted by the immune system
to face a great variety of antigens (42). Natalizumab has been
shown to reduce immune surveillance modulating immune cell
populations and subpopulations (43–45). Therefore, the reduced
TCR diversity of CD8+ naive cells in our NTZ repertoires
may reflect decreased immune protection. This finding is in
contrast with previous TCR spectra-typing studies (18) and from
PB clone distribution analysis of CD8+ T cells in Rasmussen
encephalitis, where the TCR repertoire of CD8+ lymphocytes did
not appear significantly impacted after 5 months of NTZ (46).
In our NTZ repertoires, the TCR repertoire restriction in CD8+
naive cells may depend on (auto)antigen-specific triggering,
the persistence of inflammation or both (47); indeed, serum
TNFα is increased from t0 to t24 in NTZ patients and at t24
in comparison to AHSCT (Figure S6). Furthermore, we found
that TCR clonal expansion differed by treatment (Figure 2).
Specifically, given the role of the HLA-DRB1∗1501 in MS
susceptibility (4, 22, 37), it was interesting to detect the impact of
HLA-DRB1∗1501 on CD4+ clonal expansion (Figure 2B). Major
Histocompatibility Complex (MHC) haplotype was previously
also shown to be implicated in TCR repertoire biology in other
studies (48). We did not observe any clustering based on T-
cell subpopulations functional status, for example, EM, CM,
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FIGURE 5 | T-cell receptor repertoire architecture is impacted by RRMS treatment. (A) Heatmap of the degree distribution of all (private and public) clones. The
degree of a clone is the number of clones that is similar to [LD of 1; 1 amino acid (a.a.) change apart]. Color bars on the top of the heatmap indicate treatment (AHSCT
in red, NTZ in blue), T-cell subpopulation (different shades of pink or green are reported for CD4+ or CD8+ subpopulations, respectively), timepoint (t0–t24 in light and
dark blue, respectively), and HLA class II of patients when DR1501+ (white) or DR1501– (black). The heatmap x-axis labels indicate T-cell subpopulation, and the
y-axis labels indicate clone degree from 0 (no clones similar to a clone) to 3 (three clones similar to a given clone). Hierarchical clustering was based on Euclidean
(Continued)
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FIGURE 5 | distance. (B,C) Representative TCR repertoire architectures, displayed as clone networks, of the NTZ patient Ty25, CD4CM cells, t24 and of the AHSCT
patient MS002, CD8 memory cells, t24. Each point, or “node” in the network graph, represents an amino acid CDR3 sequence (CDR3–a.a.) and links between nodes
connect CDR3s–a.a. based on LD = 1. Node size scales with log clone frequency and node color indicate private (purple) or public (orange) clones (see legend).
(D) Percentage of connected private (upper panel), public (middle panel), or all (lower panel) clones in T-cell subpopulations of AHSCT (in red) and NTZ (in blue)
patients at t0 (left) and t24 (right). T-cell subpopulations are reported on the x-axis for both time points in the following order from left to right: CD4 naive, CD4 memory,
CD4CM, CD4 EM, CD8 naive, CD8 memory, CD8CM, CD8 EM, CD8 TEMRA. Statistical significance was determined by Wilcoxon test (*p < 0.05; **p < 0.01).
FIGURE 6 | Autologous hematopoietic stem cell transplantation patients show higher TCR sequence similarity compared to NTZ patients. Heatmap of the Pearson
correlation of CDR3 k-mer decomposition profiles. Color bars on the top of the heatmap indicate treatment (AHSCT in red, NTZ in blue), T-cell subpopulation (different
shades of pink or green are reported for CD4+ or CD8+ subpopulations, respectively), timepoint (t0–t24 in light and dark blue, respectively), and HLA class II of
patients when DR1501+ (white) or DR1501– (black). The heatmap x-axis labels indicate T-cell subpopulation, and the y-axis labels indicate sample name. Due to the
high number of total samples (160), it is necessary to magnify the figure to read the labels. All CDR3s–a.a. from each patient’s TCR repertoire were deconstructed into
overlapping sub-272 sequences (“k-mers”) of length 3 (k = 3). Subsequently, all k-mers were condensed into a k-mer frequency distribution (k-mer decomposition
profile) containing each k-mer’s frequency across all CDR3s of a given repertoire. Hierarchical clustering of decomposition profiles was performed based on
correlation-based distance.
and TEMRA in NTZ patients (Figure 2), supporting the fact
that pooling memory T cells in AHSCT patients did not affect
the comparative analysis between the two groups of patients.
Indeed, T-cell subpopulations may be differently distributed in
MS, for example, cerebrospinal fluid distribution of memory EM
and CM cells, or CD4+ and CD8+ T cell proportion in white
matter lesions (49). In our approach, although we specifically
addressed TCR repertoire diversity in a longitudinal comparison
between different T-cell subpopulations, we did not observe any
associations. This may be due to the fact that we were analyzing
circulating cells or to the dimension of the sample.
Previously, Muraro et al. (11) described a skewed CD8+ TCR
repertoire after AHSCT; in our study, we did not find any similar
significant variation when comparing t0 and t24. Furthermore, in
the same work, the authors did not detect any clonal persistence
among CD4+ subpopulations before and after transplantation,
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FIGURE 7 | CD8 naive cells of natalizumab patients show a lower CDR3 sequence overlap with public databases compared to AHSCT at t24. CDR3 sequence
overlap with McPAS-TCR (A), VDJdb (B), and TCRβ sequencing databases of two MS patients from Jelcic et al. (4) (C). CDR3 sequence overlap is reported as
absolute number (upper panel in each graph) or relative percentage (lower panel in each graph) between AHSCT (in red) and NTZ (in blue) patients at t0 (left panel in
each graph) and at t24 (right panel in each graph), shown by T-cell subpopulations. Statistical significance was determined by the Wilcoxon test (*p < 0.05; **p < 0.01).
concluding that all clones were depleted by the treatment. Here,
we found that in each patient considerable clonal persistence
from t0 to t24 is generally present in both groups of patients
in CD4/CD8 memory compartment (Figure 3), with some
exceptions (MS003, MS032, Ty17, Ty21, and Ty25). Nonetheless,
clonal persistence differed by treatment: NTZ preserved CD4+
and CD8+ memory clones to a higher extent compared to
AHSCT, where clonal persistence is slightly more pronounced
only in memory CD8+ T cells. Of note, patient MS032 showed
the highest percentage of clonal persistence from t0 to t24
among all AHSCT patients. Interestingly, this patient interrupted
the standard protocol of conditioning chemotherapy for safety
reasons and is also the only one who experienced a relapse at
t24. In NTZ, where the periphery is supposed to be enriched by
pathogenic clones due to the NTZ’s mechanism of action, clonal
persistence is generally higher compared to AHSCT patients,
except for Ty17, Ty21, and Ty25, whom two-thirds (Ty21 and
Ty25) had a relapse during treatment. In light of these results,
it is tempting to speculate that evaluating clonal persistence in
specific memory T-cell subpopulations may contribute to predict
the patient outcome to treatment in the future.
The repertoire architecture describes the TCR repertoire
organization by quantifying clone-to-clone sequence similarity.
In this context, T-cell clones carrying similar CDR3s–a.a.
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FIGURE 8 | The majority of the shared sequences between RRMS cohorts and public TCR databases are viral infection associated. The absolute number of
overlapping CDR3 sequences between McPAS-TCR (A) or VDJdb (B) TCR databases and AHSCT (in red) or NTZ (in blue) patients at t0 (upper panel in each graph)
and at t24 (lower panel in each graph) shown by disease type. Statistical significance was determined by Wilcoxon test (*p < 0.05; **p < 0.01).
may have been selected by a common force, such as V(D)J
recombination, thymic selection, antigen encounter, and, in this
case, immunomodulatory treatment (30, 40, 50). We found that
methods quantifying repertoire architecture, network, and k-mer
subsequence similarity analysis were able to readily distinguish
between treatments (Figures 5, 6). We found that both CD4
and CD8 architectures differed across treatment groups, and
that effect was observable both in the public and private
compartment. More specifically, we found a greater percentage
of connected private and public clones at t24 in CD8+ naive T
cells of NTZ group compared to AHSCT (Figure 5D), together
with a lower number of public clones (Figures 4A,C). This
observation in CD8 naive cells of NTZ patients, along with
a significantly lower number of shared CDR3s with published
databases (Figure 7) and the decreased number of clones and S-E
mean value at t24 (Figure 1C), may be linked to a mild impact of
NTZ on VLA-4 expression on the surface of naive cells compared
to memory subpopulations, as previously documented (51), with
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the consequence of an increased thymic retention of this cell
population (52). It would be worthwhile to investigate how long
this effect lasts after NTZ interruption and if it may be, in part, the
culprit of the higher incidence of infection-related adverse events
observed in patients that shifted treatment, for example, from
NTZ to AHSCT (53). Furthermore, the higher TCR sequence
similarity in AHSCT patients compared to NTZ (Figure 6)
may depend on the fact that AHSCT patients underwent the
same posttransplant protocol, remaining at least 1 month in a
sterile chamber, sharing the same nutritional restrictions and the
same antimicrobial therapies. Our data do not suggest a role of
previous first-line therapies in the variation of TCR dynamics;
therapies were randomly distributed in the two cohorts and are
variable intra and inter patients groups.
The fact that treatment groups may be differentiated based
on public clones as well as the fact that we found a group of
clones that were uniquely observed in the AHSCT compartment
let us think that, in the future, it would be worthwhile
to perform a study on a larger cohort with more patients
and deeper sequencing depth, possibly also in other T-cell
subpopulations such as regulatory T cells (36). Furthermore,
it is of interest that repertoires of both groups of patients
were enriched in viral disease–associated TCRs (Figures 8A,B).
Whether these TCRs are involved in therapy outcome remains
to be determined. Recently, our group analyzed antibody titers
in patients after transplantation (data presented at EBMT 2018,
Bone Marrow Transplantation 2018; 53:210) and found that, after
engraftment (24 months), the range of a loss of protection is
between 11% and 44%. Indeed, in a subgroup of patients, the
immune memory against viruses was found to be preserved;
when it is not, revaccination is recommended after careful
evaluation of the possible disease reactivation risk (54). Indeed,
the interplay between MS and viral response in terms of
pathogenesis has always been suggested, and it is intriguing
that in our samples, among virus-associated sequences, EBV-
associated ones are the most represented (Figure 8). On the other
hand, there are still few MS-associated sequences in the public
TCR datasets, probably because they are difficult to be defined
in the absence of a known MS antigen, and this may be in
part responsible for our results. In general, more information is
needed on how distributions of antigen-specific TCRs vary across
disease states (35, 36).
To sum up, repertoire sequencing statistics examined
longitudinally patient by patient suggest that, even though
we were able to distinguish the two treatments, describing
the TCR repertoire dynamics is a personal matter: each
patient has his/her own repertoire and shows an individual
treatment response (Figure S1). However, when leveraging
computationally immunology investigating multiple different
aspects of repertoire diversity, we found that clonal expansion
(Figure 2), clonal persistence (Figure 3), public clones number
(Figure 4), and repertoire architecture (Figure 5) differentiate
readily between treatment groups. Specifically, for NTZ, there is a
trend toward a status of incomplete immune reconstitution that
becomes significant in CD8+ naive T cells, whereas in AHSCT
there is an almost complete TCR repertoire reconstitution in all
subpopulations investigated.
In conclusion, our work demonstrates that investigating
MS patient TCR repertoires during immunomodulatory
treatments by deep sequencing methodologies applied on T-cell
subpopulations and followed by rigorous statistical analysis
enables to distinguish the different treatment effects on immune
response and suggests a possible bridge between molecular
data and clinical data. In light of this, we believe that, in
the future, tracking TCR repertoire dynamics during RRMS
treatments might accompany the clinical evaluation of patients
as a supportive tool to understand the disease pathogenesis,
the disease-modifying treatment impact on adaptive immune
response, and treatment outcome and risk.
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